Home › Companies › CLRB

Cellectar Biosciences

Market cap $9.2M 10.0M shares (10-Q, Nov 6, 2026) × $0.920 close Nov 17, 2026

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. FinancingLate 2026 / early 2027Financing, Late 2026 / early 2027, routine
  2. CLR 125 Ph1 interim4Q 2026CLR 125 Ph1 interim, 4Q 2026, major
  3. Iopofosine I 131 Ph3 startEarly 2027Iopofosine I 131 Ph3 start, Early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

PDC

Phospholipid ether drug conjugate (PDC) platform designed to selectively deliver a diverse range of oncologic payloads to cancer cells via lipid raft-mediated uptake. Supports radioconjugates (PRCs), small molecule, peptide, and oligonucleotide payloads. Focus: broad cancer indications including hematologic malignancies and solid tumors.

Phospholipid Drug Conjugate

Proprietary PDC delivery platform leveraging phospholipid ether (PLE) technology for targeted cancer cell delivery; combinable with small-molecule chemotherapeutics, radiotherapeutics, and other therapeutic molecules; focus areas include hematologic malignancies and solid tumors

Discontinued (3)

Capital (as filed)

Cash
$24.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$9.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$24.6M cash, runway into the second quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Cellectar Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Cellectar Biosciences (CLRB) - Scientific Deep Dive for Iopofosine and Pipeline Products Strong science and removed bankruptcy risk, but complex warrant structure and execution risk warrant patience before taking a position.
  2. Watch UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Live Watch list maintained with downgraded urgency as 52.65M warrant shares create a structural ceiling, NDA slipped to mid-2027, and another financing raise appears likely before the key catalyst.
  3. Avoid UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Dark Downgraded to Avoid as milestone warrants are now effectively unreachable at $1.22, only ~two quarters of runway remain, and a deeply dilutive pre-NDA raise appears nearly unavoidable.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (28)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)